NASDAQ:CDXS - Codexis Stock Price, Price Target & More

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Codexis, Inc. (NASDAQ:CDXS) posted its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.02. The biotechnology company earned $14.04 million during the quarter, compared to analysts' expectations of $13.50 million. Codexis had a negative net margin of 36.06% and a negative return on equity of 87.65%. View Codexis' Earnings History.

4 analysts have issued 12-month price targets for Codexis' stock. Their predictions range from $11.00 to $18.00. On average, they expect Codexis' share price to reach $14.25 in the next twelve months. This suggests that the stock has a possible downside of 10.4%. View Analyst Ratings for Codexis.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Codexis include Sensient Technologies (SXT), Westlake Chemical Partners (WLKP), Green Plains (GPRE), Renewable Energy Group (REGI), FutureFuel (FF), Green Plains Partners (GPP), REX American Resources (REX), Amyris (AMRS), Sino United Worldwide Consolidated (SUIC), Pacific Ethanol (PEIX), Tantech (TANH), Wave Sync (WAYS), CTD (CTDH), Aemetis (AMTX) and Gevo (GEVO).

News stories about CDXS stock have trended positive recently, Accern Sentiment reports. Accern identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Codexis earned a media sentiment score of 0.26 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 44.75 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Codexis' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (4.97%), Comprehensive Portfolio Management LLC (0.11%) and Campbell & CO Investment Adviser LLC (0.02%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Michael D Aldridge, Pam P Cheng, Patrick Y Yang, Thomas R Baruch, Ventures Fund Vii LP Vivo, Ventures Vii Affiliates F Vivo and Vivo Ventures Vii, Llc. View Institutional Ownership Trends for Codexis.

CDXS stock was sold by a variety of institutional investors in the last quarter, including Comprehensive Portfolio Management LLC. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Byron L Dorgan, David V Smith, Dennis P Wolf, Gordon Sangster, James Lalonde, John J Nicols, Michael D Aldridge, Pam P Cheng, Patrick Y Yang, Thomas R Baruch and Ventures Vii Affiliates F Vivo. View Insider Buying and Selling for Codexis.

CDXS stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co. and Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Codexis.

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CDXS stock can currently be purchased for approximately $15.90.

Codexis has a market capitalization of $838.54 million and generates $50.02 million in revenue each year. The biotechnology company earns $-22,990,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Codexis employs 116 workers across the globe.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]